Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24022436 | 0.89 | DPP8 (0.34) | GHSRDPP8DPP9KDM4D | |
| SCHEMBL24386639 | 0.86 | ALDH1A1 (0.32) | GHSRDPP8DPP9KDM4D | |
| SCHEMBL29920736 | 0.73 | AKR1B1 (0.34) | HPGDKDM4D | |
| SCHEMBL18162819 | 0.66 | KMT2A (0.37) | GHSRDPP8DPP9KDM4E | |
| SCHEMBL25381097 | 0.65 | HDAC4 (0.36) | GHSRDPP8DPP9 | |
| SCHEMBL21452458 | 0.65 | HDAC4 (0.36) | GHSRDPP8DPP9 | |
| SCHEMBL3372646 | 0.64 | CTSK (0.35) | KDM4E | |
| SCHEMBL15295683 | 0.64 | CTSK (0.39) | — | |
| SCHEMBL25859667 | 0.63 | KDM4D (0.31) | KDM4D | |
| SCHEMBL1350187 | 0.63 | AKR1B1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135577-A1 | DIHYDROPYRAZOLOPYRAZINONE DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135577-A1 | DIHYDROPYRAZOLOPYRAZINONE DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY | MGAT2, MGAT1, SLC6A5 | GHSR 956/4885DPP8 1121/4885DPP9 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.